Brain shrinkage associated with Alzheimer’s therapies shows effectiveness rather than harm

A loss of brain volume associated with new immunotherapies for Alzheimer’s disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue,

Molecular zip code draws killer T cells straight to brain tumors

Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice. The technology will soon be tested in a clinical

Key pathway leading to neurodegeneration in early stages of ALS identified

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers